AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22311903 — intervention group
Group type: COMPARATOR
Intervention: Yohimbine (5.4 mg)
Number of subjects: 17
Study 22311903 — intervention group
Group type: COMPARATOR
Intervention: Atomoxetine (18.0 mg)
Number of subjects: 17
Study 22311903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 20102071 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with glasses
Number of subjects: 54
Study 20102071 — intervention group
Group type: COMPARATOR
Intervention: Subjects without glasses
Number of subjects: 54
Study 17728707 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 2103
Study 17728707 — intervention group
Group type: COMPARATOR
Intervention: Calcium-based phosphate binders
Number of subjects: 2103
Study 15215661 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing instruction with re-instruction and reminder messages (Experimental Group)
Number of subjects: 26
Study 15215661 — intervention group
Group type: COMPARATOR
Intervention: No follow-up intervention (Control Group)
Number of subjects: 26
Study 12218962 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterogeneous plaque (group A)
Number of subjects: 391
Study 12218962 — intervention group
Group type: COMPARATOR
Intervention: Homogeneous plaque (group B)
Number of subjects: 391
Study 9846921 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram (0.5 mg kg(‐1)h(‐1)) in combination with caffeine
Number of subjects: 29
Study 9846921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 9175807 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 32
Study 9175807 — intervention group
Group type: COMPARATOR
Intervention: Control (atenolol or placebo)
Number of subjects: 32
Study 2030246 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg methylphenidate
Number of subjects: 0
Study 2030246 — intervention group
Group type: EXPERIMENTAL
Intervention: methylphenidate
Number of subjects: 0
Study 2030246 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 6103707 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.5 mg oral
Number of subjects: 3
Study 6103707 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1.0 mg oral
Number of subjects: 3
Study 6103707 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2.0 mg oral
Number of subjects: 3
Study 6103707 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam i.m. administration
Number of subjects: 3
Study 6103707 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (all doses)
Number of subjects: 3
Study 31826024 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of 'Movie Models' video intervention within six Feel4Diabetes counselling sessions.
Number of subjects: 126
Study 31826024 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified in detail).
Number of subjects: 126
Study 27869661 — intervention group
Group type: EXPERIMENTAL
Intervention: LAB⁴ANTI (30 billion CFU·day‐1)
Number of subjects: 30
Study 27869661 — intervention group
Group type: EXPERIMENTAL
Intervention: LAB⁴ (matched pro/prebiotic)
Number of subjects: 30
Study 27869661 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 30
Study 27869661 — intervention group
Group type: EXPERIMENTAL
Intervention: LAB⁴ANTI and LAB⁴
Number of subjects: 30
Study 23375074 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodised salt (IS) in cooking and at the table
Number of subjects: 131
Study 23375074 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg potassium iodide (KI)/d
Number of subjects: 131
Study 23375074 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 μg potassium iodide (KI)/d
Number of subjects: 131
Study 23375074 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 131
Study 20549511 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (IMN) 40 mg
Number of subjects: 40
Study 20549511 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol 40 mg vaginally
Number of subjects: 40
Study 19801226 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater palatine nerve block
Number of subjects: 40
Study 19801226 — intervention group
Group type: EXPERIMENTAL
Intervention: High tuberosity nerve block
Number of subjects: 40
Study 16986383 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (unfractionated or low-molecular-weight)
Number of subjects: 0
Study 16986383 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf compression methods
Number of subjects: 0
Study 16986383 — intervention group
Group type: EXPERIMENTAL
Intervention: Current methods of venous thromboprophylaxis
Number of subjects: 0
Study 15717699 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-through-needle (NTN) technique
Number of subjects: 200
Study 15717699 — intervention group
Group type: COMPARATOR
Intervention: Double-space technique
Number of subjects: 200
Study 11707786 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravenous approach using 5 mL mepivacaine
Number of subjects: 20
Study 11707786 — intervention group
Group type: COMPARATOR
Intervention: Blind subcutaneous injection using 5 mL mepivacaine
Number of subjects: 20
Study 11707786 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravenous approach
Number of subjects: 20
Study 11707786 — intervention group
Group type: COMPARATOR
Intervention: Blind subcutaneous injection
Number of subjects: 20
Study 9172850 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate backrub after turning to the left side
Number of subjects: 57
Study 9172850 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed backrub after turning to the left side
Number of subjects: 57
Study 9172850 — intervention group
Group type: EXPERIMENTAL
Intervention: Turning to the left side
Number of subjects: 57
Study 9172850 — intervention group
Group type: EXPERIMENTAL
Intervention: Turning and immediate backrub
Number of subjects: 57
Study 9172850 — intervention group
Group type: EXPERIMENTAL
Intervention: Turning and delayed backrub
Number of subjects: 57
Study 8147063 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0
Study 8147063 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers
Number of subjects: 0
Study 3533129 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol 40 mg once daily
Number of subjects: 12
Study 3533129 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg twice daily
Number of subjects: 12
Study 29955032 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 48
Study 29955032 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 48
Study 27380464 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (IIV3)
Number of subjects: 2049
Study 27380464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2049
Study 24938492 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Led Assessment for Network Support (PLANS) intervention
Number of subjects: 20
Study 22810739 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptol
Number of subjects: 75
Study 20970090 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based substance use prevention program (9 sessions)
Number of subjects: 108
Study 20970090 — intervention group
Group type: COMPARATOR
Intervention: Test-only control arm
Number of subjects: 108
Study 18829215 — intervention group
Group type: EXPERIMENTAL
Intervention: Corridor-based functional performance measures (6-minute walk, walking velocity over four meters at usual and fastest pace, SPPB)
Number of subjects: 156
Study 18829215 — intervention group
Group type: COMPARATOR
Intervention: Treadmill walking measures
Number of subjects: 156
Study 15871020 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal Thickness Analyzer (RTA)
Number of subjects: 22
Study 15871020 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Number of subjects: 22
Study 15871020 — intervention group
Group type: COMPARATOR
Intervention: Inter-examiner analysis for RTA and OCT
Number of subjects: 22
Study 12381090 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (1.5 microg x kg(‐1) min(‐1))
Number of subjects: 22
Study 12381090 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (0.5 microg x kg(‐1) min(‐1))
Number of subjects: 22
Study 10480632 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (50 microM)
Number of subjects: 30
Study 10480632 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine treatment
Number of subjects: 30
Study 10480632 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine treatment after 1 week
Number of subjects: 30
Study 10480632 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal analysis
Number of subjects: 30
Study 8665548 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (5 mg b.i.d.)
Number of subjects: 20
Study 8665548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2014933 — intervention group
Group type: EXPERIMENTAL
Intervention: Volmax, 8 mg bid
Number of subjects: 38
Study 2014933 — intervention group
Group type: COMPARATOR
Intervention: Proventil Repetabs, 8 mg (as two 4-mg tablets) bid
Number of subjects: 38
Study 2014933 — intervention group
Group type: COMPARATOR
Intervention: Volmax and Proventil Repetabs
Number of subjects: 38
Study 12338165 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 18
Study 12338165 — intervention group
Group type: EXPERIMENTAL
Intervention: Alclofenac
Number of subjects: 18
Study 12338165 — intervention group
Group type: EXPERIMENTAL
Intervention: Flufenamic acid
Number of subjects: 18
Study 12338165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31287141 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted linoleic acid (LA)
Number of subjects: 19954
Study 29203772 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oral challenge
Number of subjects: 19
Study 29203772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 25658929 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-form mindfulness-based stress reduction
Number of subjects: 23
Study 23899913 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard practice investigations plus additional monitoring (SP-AM)
Number of subjects: 100
Study 23899913 — intervention group
Group type: COMPARATOR
Intervention: Standard practice investigations (SP)
Number of subjects: 100
Study 21088591 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary mid‐forearm tourniquet for 8 min during and after administration of local anaesthetic
Number of subjects: 50
Study 21088591 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tourniquet)
Number of subjects: 50
Study 19762295 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 228
Study 19762295 — intervention group
Group type: COMPARATOR
Intervention: Non-nutritive sucking-placebo
Number of subjects: 228
Study 19762295 — intervention group
Group type: COMPARATOR
Intervention: Non-nutritive sucking-24% sucrose
Number of subjects: 228
Study 19762295 — intervention group
Group type: COMPARATOR
Intervention: Other analgesic procedures
Number of subjects: 228
Study 17974114 — intervention group
Group type: EXPERIMENTAL
Intervention: VISIT navigation system
Number of subjects: 16
Study 17974114 — intervention group
Group type: COMPARATOR
Intervention: Medtronic StealthStation Treon navigation system
Number of subjects: 16
Study 15347340 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepotastine (10 mg twice a day)
Number of subjects: 7
Study 15347340 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg once a day)
Number of subjects: 7
Study 15347340 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine (60 mg twice a day)
Number of subjects: 7
Study 15347340 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine (5 mg twice a day)
Number of subjects: 7
Study 15347340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 11394422 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic laser surgery
Number of subjects: 56
Study 9868589 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants from food; specific dosage and duration not available.
Number of subjects: 0
Study 9868589 — intervention group
Group type: COMPARATOR
Intervention: Antioxidant therapy; specific details not available.
Number of subjects: 0
Study 7993987 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 10 mg controlled-release nifedipine tablets (Adalat Retard, Bayer), administered 12 hourly
Number of subjects: 46
Study 7993987 — intervention group
Group type: EXPERIMENTAL
Intervention: One 20 mg controlled-release nifedipine tablet (Adalat Retard, Bayer), administered 12 hourly
Number of subjects: 46
Study 7993987 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 30 mg nifedipine gastro-intestinal therapeutic system (GITS) tablets (Adalat XL, Bayer), administered once daily
Number of subjects: 46
Study 7993987 — intervention group
Group type: EXPERIMENTAL
Intervention: One 60 mg nifedipine GITS tablet (Adalat XL, Bayer), administered once daily
Number of subjects: 46
Study 7993987 — intervention group
Group type: EXPERIMENTAL
Intervention: One 20 mg plus one 10 mg nifedipine controlled-release tablet (Adalat Retard, Bayer), administered 12 hourly
Number of subjects: 46
Study 7993987 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS products (Adalat XL)
Number of subjects: 46
Study 2839742 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including phone calls from nurses, mailings of appointment reminders, lists of early warning signs, and prompt rescheduling of visit failures
Number of subjects: 1001
Study 2839742 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 1001
Study 2839742 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention for high-risk patients (N = 181)
Number of subjects: 1001
Study 2839742 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1001
Study 2839742 — intervention group
Group type: COMPARATOR
Intervention: Control group for high-risk patients (N = 181)
Number of subjects: 1001
Study 31790904 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-finding strategy (history taking, physical examination, blood tests, electrocardiography, spirometry, and echocardiography)
Number of subjects: 829
Study 31790904 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 829
Study 31790904 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-finding strategy
Number of subjects: 829
Study 31489810 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative respiratory muscle endurance training (RMET) for 3 weeks
Number of subjects: 26
Study 31489810 — intervention group
Group type: COMPARATOR
Intervention: Control group (C group) with usual chest physical therapy only
Number of subjects: 26
Study 31489810 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative respiratory muscle endurance training (RMET)
Number of subjects: 26
Study 28060065 — intervention group
Group type: EXPERIMENTAL
Intervention: SS-OCT
Number of subjects: 29
Study 25721152 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT‐12 olfactory screening test
Number of subjects: 100
Study 23062403 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-month educational and playful intervention
Number of subjects: 1216
Study 23062403 — intervention group
Group type: COMPARATOR
Intervention: Usual curriculum
Number of subjects: 1216
Study 21868252 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) preconditioning for 5 days before surgery in on‐pump patients
Number of subjects: 49
Study 21868252 — intervention group
Group type: COMPARATOR
Intervention: Control group (on‐pump surgery without HBO)
Number of subjects: 49
Study 21868252 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) preconditioning for 5 days before surgery in off‐pump patients
Number of subjects: 49
Study 21868252 — intervention group
Group type: COMPARATOR
Intervention: Control group (off‐pump surgery without HBO)
Number of subjects: 49
Study 18834731 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diazepam 10 mg (n = 65)
Number of subjects: 130
Study 18834731 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 65)
Number of subjects: 130
Study 17176914 — intervention group
Group type: EXPERIMENTAL
Intervention: EVAL membrane
Number of subjects: 11
Study 17176914 — intervention group
Group type: COMPARATOR
Intervention: VE-C membrane
Number of subjects: 11
Study 17176914 — intervention group
Group type: COMPARATOR
Intervention: PS membrane
Number of subjects: 11
Study 15065315 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline adherence (YES-GL)
Number of subjects: 123
Study 15065315 — intervention group
Group type: COMPARATOR
Intervention: Normal clinical practice (NO-GL)
Number of subjects: 123
Study 10812581 — intervention group
Group type: EXPERIMENTAL
Intervention: ciprofibrate 100 mg
Number of subjects: 13
Study 8849609 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic automated border detection (ABD)
Number of subjects: 42
Study 1290434 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 200 mg induction dose
Number of subjects: 11
Study 1290434 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 200 mg maintenance dose
Number of subjects: 11
Study 1290434 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 50 mg and 100 mg maintenance doses
Number of subjects: 11
Study 1290434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 6365158 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 118
Study 6365158 — intervention group
Group type: EXPERIMENTAL
Intervention: Arnica Montana
Number of subjects: 118
Study 6365158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 31006420 — intervention group
Group type: EXPERIMENTAL
Intervention: Brown rice regimen (parboiled brown rice)
Number of subjects: 166
Study 28947365 — intervention group
Group type: EXPERIMENTAL
Intervention: DEE transarterial chemoembolization (n = 6)
Number of subjects: 12
Study 28947365 — intervention group
Group type: COMPARATOR
Intervention: TAE (n = 5)
Number of subjects: 12
Study 28947365 — intervention group
Group type: EXPERIMENTAL
Intervention: DEE transarterial chemoembolization (n = 4)
Number of subjects: 12
Study 28947365 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DEE and TAE
Number of subjects: 12
Study 26952125 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-flush
Number of subjects: 50
Study 25141094 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of female athletes' weights in athletic event programs
Number of subjects: 152
Study 25141094 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavier athletes vs. less heavy athletes
Number of subjects: 152
Study 21922202 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg betamethasone i.v. prior to vinorelbine infusion
Number of subjects: 79
Study 21922202 — intervention group
Group type: COMPARATOR
Intervention: Placebo i.v. prior to vinorelbine infusion
Number of subjects: 79
Study 21922202 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml saline infusion post vinorelbine infusion
Number of subjects: 79
Study 21922202 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ml saline infusion post vinorelbine infusion
Number of subjects: 79
Study 20076843 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin therapy (INR target 1.8, range 1.5-2.0)
Number of subjects: 267
Study 20076843 — intervention group
Group type: COMPARATOR
Intervention: Standard-intensity warfarin therapy (INR target 2.5, range 2.0-3.0)
Number of subjects: 267
Study 20076843 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin therapy
Number of subjects: 267
Study 20076843 — intervention group
Group type: COMPARATOR
Intervention: Standard-intensity warfarin therapy
Number of subjects: 267
Study 17407215 — intervention group
Group type: EXPERIMENTAL
Intervention: PYD/exercise
Number of subjects: 165
Study 17407215 — intervention group
Group type: COMPARATOR
Intervention: Placebo/exercise
Number of subjects: 165
Study 17407215 — intervention group
Group type: EXPERIMENTAL
Intervention: PYD/diet recall
Number of subjects: 165
Study 17407215 — intervention group
Group type: COMPARATOR
Intervention: Placebo/diet recall
Number of subjects: 165
Study 15827573 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS MPH 18 mg
Number of subjects: 47
Study 15827573 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS MPH 36 mg
Number of subjects: 47
Study 15827573 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS MPH 54 mg
Number of subjects: 47
Study 15827573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 12485320 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to fungi (molds and yeasts) in children attending a water-damaged school
Number of subjects: 0
Study 12485320 — intervention group
Group type: COMPARATOR
Intervention: Unexposed children of the same age
Number of subjects: 0
Study 9835257 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (n = 30)
Number of subjects: 59
Study 9835257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (n = 29)
Number of subjects: 59
Study 9835257 — intervention group
Group type: COMPARATOR
Intervention: Combined aspirin and ticlopidine (nonrandomized group III, n = 31)
Number of subjects: 59
Study 7861711 — intervention group
Group type: EXPERIMENTAL
Intervention: IDDM adolescents with microalbuminuria (MA)
Number of subjects: 50
Study 7861711 — intervention group
Group type: EXPERIMENTAL
Intervention: IDDM adolescents without microalbuminuria (non-MA)
Number of subjects: 50
Study 7861711 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined IDDM group
Number of subjects: 50
Study 7861711 — intervention group
Group type: COMPARATOR
Intervention: Control siblings of MA subgroup
Number of subjects: 50
Study 2570104 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin for 1 day
Number of subjects: 423
Study 2570104 — intervention group
Group type: COMPARATOR
Intervention: Penicillin for 5 days
Number of subjects: 423
Study 894653 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital stripping of the membranes from the lower uterine segment
Number of subjects: 91
Study 894653 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 91